Get started
Novavax, Inc.Novavax, Inc.Novavax, Inc.

Novavax, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Novavax, Inc.



Key stats


Market capitalization
‪2.09 B‬ USDMid cap
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.52 USD
Net income (FY)
‪440.30 M‬ USD
Revenue (FY)
‪1.12 B‬ USD
Shares float
‪156.74 M‬
Beta (1Y)
2.39

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
749
Change (1Y)
−203−21.32%
Revenue / Employee (1Y)
‪1.50 M‬ USD
Net income / Employee (1Y)
‪587.85 K‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
John C.s Jacobs
Website
novavax.com
Headquarters
Gaithersburg
Founded
1987
IPO date
May 16, 1973
ISIN
US6700024010
CUSIP
670002401
FIGI
BBG000NVSBL7
Identifiers
ISIN US6700024010
CFI code
ESVUFR
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral

Analyst rating


An aggregate view of professional's ratings.
Neutral
Neutral
Neutral

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight0.59%
Market value‪60.61 M‬
IWM
iShares Russell 2000 Index Fund
Weight0.07%
Market value‪50.71 M‬
VBK
Vanguard Morningstar Small-Cap Growth ETF
Weight0.04%
Market value‪20.30 M‬
IWN
iShares Russell 2000 Value ETF
Weight0.13%
Market value‪17.97 M‬
PBE
Invesco Biotechnology & Genome ETF
Weight3.74%
Market value‪15.66 M‬
IBB
iShares Biotechnology ETF
Weight0.14%
Market value‪15.41 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight0.05%
Market value‪11.02 M‬
FESM
Fidelity Enhanced Small Cap Core ETF
Weight0.15%
Market value‪9.80 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.04%
Market value‪8.22 M‬
FYC
First Trust Small Cap Growth AlphaDEX Fund
Weight0.44%
Market value‪5.90 M‬
IDNA
iShares Genomics Immunology and Healthcare ETF
Weight1.76%
Market value‪5.54 M‬

Explore more ETFs 

Frequently asked questions


The current price of NVAX is 12.71 USD — it has increased by 0.39% in the past 24 hours. Watch Novavax, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Novavax, Inc. stocks are traded under the ticker NVAX.
NVAX stock has risen by 2.91% compared to the previous week, the month change is a 36.81% rise, over the last year Novavax, Inc. has showed a 50.77% increase.
We've gathered analysts' opinions on Novavax, Inc. future price: according to them, NVAX price has a max estimate of 25.00 USD and a min estimate of 7.00 USD. Watch NVAX chart and read a more detailed Novavax, Inc. stock forecast: see what analysts think of Novavax, Inc. and suggest that you do with its stocks.
NVAX reached its all-time high on Feb 9, 2021 with the price of 331.68 USD, and its all-time low was 3.53 USD and was reached on Feb 5, 2024. View more price dynamics on NVAX chart.
See other stocks reaching their highest and lowest prices.
NVAX stock is 5.16% volatile and has beta coefficient of 2.39. Track Novavax, Inc. stock price on the chart and check out the list of the most volatile stocks — is Novavax, Inc. there?
Today Novavax, Inc. has the market capitalization of ‪2.09 B‬, it has increased by 4.72% over the last week.
Yes, you can track Novavax, Inc. financials in yearly and quarterly reports right on TradingView.
Novavax, Inc. is going to release the next earnings report on Nov 5, 2026. Keep track of upcoming events with our Earnings Calendar.
NVAX earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.38 USD resulting in a 15.75% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about Novavax, Inc. earnings.
Novavax, Inc. revenue for the last quarter amounts to ‪56.70 M‬ USD, despite the estimated figure of ‪52.51 M‬ USD. In the next quarter, revenue is expected to reach ‪77.20 M‬ USD.
NVAX net income for the last quarter is ‪−53.39 M‬ USD, while the quarter before that showed ‪−9.49 M‬ USD of net income which accounts for 0.00% change. Track more Novavax, Inc. financial stats to get the full picture.
No, NVAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 13, 2026, the company has 749 employees. See our rating of the largest employees — is Novavax, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novavax, Inc. EBITDA is ‪−101.43 M‬ USD, and current EBITDA margin is 52.59%. See more stats in Novavax, Inc. financial statements.
Like other stocks, NVAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novavax, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novavax, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novavax, Inc. stock shows the buy signal. See more of Novavax, Inc. technicals for a more comprehensive analysis.